IP Library Granted Patent US 7,884,194
Granted Patent B2
US 7,884,194 · App. 12/157,094 · Granted Feb 8, 2011

Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,884,194
App. No.
12/157,094
Granted
Feb 8, 2011
Kind
B2
Abstract

Soluble epidermal growth factor receptors 2 and 3 (HER2 and HER3) splice variant proteins with HER2 and HER3 antagonist activity and anti-proliferative properties, as well as the corresponding nucleic acids, are provided for treatment of proliferative diseases, in particular cancer. Also provided are compositions and methods for inducing expression of these splice variants, including splice switching oligonucleotides that modulate splicing of pre-mRNA that codes for these receptors.

Claims (4)

1. An isolated, soluble epidermal growth factor receptor-2 (HER2) protein consisting of the sequence set forth in SEQ ID NO:6 or amino acids 23-584 of SEQ ID NO:6.

2. The protein of claim 1 , which is modified by protein pegylation.

3. An isolated nucleic acid encoding an epidermal growth factor receptor-2 (HER2) protein according to claim 1 .

4. The nucleic acid of claim 3 , consisting of the sequence set forth in SEQ ID NO: 5 or nucleotides 67-1755 of SEQ ID NO:5.

Assignments (2)
CHANGE OF NAME Recorded May 30, 2019
From: AVI BIOPHARMA, INC.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 049315/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2009
From: KOLE, RYSZARD; SAZANI, PETER; WAN, JING
To: AVI BIOPHARMA, INC.
Reel/Frame 022082/0157 →